BACKGROUND/AIM: Perioperative nutrition and inflammation affect the oncological outcomes of various malignancies. We evaluated the clinical impact of the preoperative platelet-to-albumin ratio (PAR) in resectable esophageal cancer patients who received curative treatment. PATIENTS AND METHODS: This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. RESULTS: Based on the 3- and 5-year OS rates, we set the cut-off value for the PAR at 80×103 in the present study. Among 168 patients, 134 (79.8%) were defined as the PAR-low and 34 (20.2%) as the PAR-high group. The 3- and 5-year OS rates were 60.2% and 51.7% in the PAR-low group and 30.2% and 18.9% in the PAR-high group, respectively. There were significant differences in OS (p=0.005). The PAR was therefore selected for the final multivariate analysis model [hazard ratio=1.997, 95% confidence interval (CI)=1.230-3.241, p=0.037]. On comparing the perioperative clinical course between the PAR-high and PAR-low groups, there were marginally significant differences in the postoperative surgical complications and intraoperative blood loss between the groups. CONCLUSION: The PAR had clinical influence on the long-term oncological outcomes of esophageal cancer patients and might thus be a promising prognostic factor for esophageal cancer patients.
BACKGROUND/AIM: Perioperative nutrition and inflammation affect the oncological outcomes of various malignancies. We evaluated the clinical impact of the preoperative platelet-to-albumin ratio (PAR) in resectable esophageal cancer patients who received curative treatment. PATIENTS AND METHODS: This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. RESULTS: Based on the 3- and 5-year OS rates, we set the cut-off value for the PAR at 80×103 in the present study. Among 168 patients, 134 (79.8%) were defined as the PAR-low and 34 (20.2%) as the PAR-high group. The 3- and 5-year OS rates were 60.2% and 51.7% in the PAR-low group and 30.2% and 18.9% in the PAR-high group, respectively. There were significant differences in OS (p=0.005). The PAR was therefore selected for the final multivariate analysis model [hazard ratio=1.997, 95% confidence interval (CI)=1.230-3.241, p=0.037]. On comparing the perioperative clinical course between the PAR-high and PAR-low groups, there were marginally significant differences in the postoperative surgical complications and intraoperative blood loss between the groups. CONCLUSION: The PAR had clinical influence on the long-term oncological outcomes of esophageal cancer patients and might thus be a promising prognostic factor for esophageal cancer patients.
Authors: Manish A Shah; Erin B Kennedy; Daniel V Catenacci; Dana C Deighton; Karyn A Goodman; Narinder K Malhotra; Christopher Willett; Brendon Stiles; Prateek Sharma; Laura Tang; Bas P L Wijnhoven; Wayne L Hofstetter Journal: J Clin Oncol Date: 2020-06-22 Impact factor: 44.544
Authors: Yuichiro Doki; Jaffer A Ajani; Ken Kato; Jianming Xu; Lucjan Wyrwicz; Satoru Motoyama; Takashi Ogata; Hisato Kawakami; Chih-Hung Hsu; Antoine Adenis; Farid El Hajbi; Maria Di Bartolomeo; Maria I Braghiroli; Eva Holtved; Sandra A Ostoich; Hye R Kim; Masaki Ueno; Wasat Mansoor; Wen-Chi Yang; Tianshu Liu; John Bridgewater; Tomoki Makino; Ioannis Xynos; Xuan Liu; Ming Lei; Kaoru Kondo; Apurva Patel; Joseph Gricar; Ian Chau; Yuko Kitagawa Journal: N Engl J Med Date: 2022-02-03 Impact factor: 176.079